Join Growin Stock Community!

Dyne therapeutics, inc.DYN.US Overview

US StockHealthcare
(No presentation for DYN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DYN AI Insights

DYN Overall Performance

DYN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DYN Recent Performance

-2.43%

Dyne therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

DYN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DYN Key Information

DYN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DYN Profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Price of DYN

DYN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DYN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.86
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.86
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DYN's latest earnings report released?

    The most recent financial report for Dyne therapeutics, inc. (DYN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DYN's short-term business performance and financial health. For the latest updates on DYN's earnings releases, visit this page regularly.

  • How much debt does DYN have?

    As of the end of the reporting period, Dyne therapeutics, inc. (DYN) had total debt of 20.28M, with a debt ratio of 0.14. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does DYN have?

    At the end of the period, Dyne therapeutics, inc. (DYN) held Total Cash and Cash Equivalents of 893.37M, accounting for 0.75 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DYN's EPS continuing to grow?

    According to the past four quarterly reports, Dyne therapeutics, inc. (DYN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.76. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DYN?

    Dyne therapeutics, inc. (DYN)'s Free Cash Flow (FCF) for the period is -112.32M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 46.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.